Abstract
The 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal (Colorectal) Cancer Track included several notable presentations. The addition of cetuximab to FOLFOX in stage III colon cancer did not improve disease-free survival, but increased toxicity. In the metastatic setting, cetuximab demonstrated benefit only in a small subset of patients (KRAS wild-type and limited metastatic disease). Bevacizumab monotherapy may be equivalent to combination chemotherapy in the maintenance phase of treatment in advanced disease, and in another study bevacizumab did not appear to incur excess morbidity in patients with an intact primary tumor. Alternate strategies for the treatment of stage II/III rectal cancer included short-course radiotherapy with adjuvant chemotherapy and neoadjuvant FOLFOX–bevacizumab without radiation, both demonstrating promising results.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.